stranglehold of the manufacture of t3 by concordia

I would like some feedback on the question as to why concordia has the sole rights to manufacure and distribute t3 why there could potentially be another company that could produce. Our own.

boots contract manufacturing in beeston is regulated by the mrha and contracts for proctor and gamble and glaxo smith kline and reckitt and benckiser as well as making a well known face serum you can look younger whilst you feel 90 lol it is also owned by walgreens as a mother company that has its own chain of pharmacys and i think they own jaysons as well boots scientists created ibuprofen and called it neurofen then sold it to reckitts but my point is boots still manufatured it under its own licence under contract

if t3 is a prescription generic drug that potentially could be manufactured some where else alot cheaper as the formula would be available as is ibuprofen then it could potentially be used more as a the cost wouldnt be an issue to the nhs and concordia would not have the strangehold and could be undercut thus making it a better alternative to just t4 for us and the nhs

also these companies all use the workplace sick system of getting people into the dole queue as in the unavailability to work if they made t3 then we wouldnt be as sick and they would have a great workfore

how much would it cost to get another pharmacuetical company to manufacture to a charity the charity supplies all the evidence from members private lab tests and we do our own researce and development and our own paper as to the value of having t3 when you a patient needs it

Can we get a different pharmaceutical company on board i meen they are greedy after all

I might start drinking decaf


Featured Content

Join our community

The community helps everyone affected by thyroid conditions by providing support, information and guidance.


Featured by HealthUnlocked

13 Replies

  • Any pharma company can apply to the MHRA to start producing T3 providing they can meet the rigorous standards required.

  • so in theory anyone or any new founded or existing charity can register a new or sister limited pharma company at companies house get vat registered cost out formula packaging distribution apply for a licence get bcm to manufacture under contract then create awareness to nhs and then supply? At the same time collating all evidence from the charity and its members and the improvements to life on t3 and being competition to concordia

    incidently bcm have a specials department that makes very rare medications

  • 'In theory' I believe anyone with spare £millions can attempt this, yes.

    helvella - didn't you do some sort of post about this a while back? xx

  • As I understand this post, the original poster is suggesting the possibility of setting up a new company to manufacture T3.


  • I was responding to their second comment.

  • i am suggesting it may not be as expensive as everyone assumes it costs approx £200 for a limited company name and registration and approx £100 to get vat registered the company could stay dormant providing you provide the accounts the formula is generic so no researce and development costs just licence unknown cost unknown raw materials manufacture costs unknown and distribution however as awful as i hate writing this clearly there is a demand so an existing company could be enticed to produce t3 or anew company set up

  • I think you may be surprised at exactly how expensive and complex it is to manufacture liothyronine, in the UK.

    It is obvious from the prices charged on the continent that things are not the same elsewhere.


  • i have just answered my own question and thank you louise for your help please find this link inspiring

    I didnt know that cytomel was the brand name and that it was purchased from glaxo smith kline.Who incidently didnt hike the prices

  • Cytomel was owned by Jones, later bought up by King, who in turn were bought up by Pfizer where that formulation and brand remains. The tablets have KPI on them which was, I think, inherited from King Pharnmaceutical.

    Glaxo developed Tertroxin, became Glaxo Smith Kline and sold Tertroxin to Goldshield. Goldshield later became Mercury Pharma, part of Amdipharm and now part of Concordia International.

  • Certainly I cannot see any fundamental reason that it could not be done. If I wanted to get product to market, I'd probably try to find an existing manufacturer and see if they would supply me as an importer.

    The organisation would have to buy-in experienced staff - think they would have to include at least a suitable pharmacist. Might find the required insurance premiums eye-watering!

    Any really big lottery winners who are dying of boredom on their fourth cruise this year, can't find any more cars they want to buy, have enough homes with electric gates and walk-in wardrobes, bars, hot tubs, etc. This would be a worthwhile spend. Have to face the possibility of losing the entire investment, though. :-)

  • Stefano pessina?

  • Looks as if he'd have the resources - but can't for the life of me see why he would do so.

  • One problem I can forsee is that as T3 in uk is a prescription only med and NHS dogma says it is unnecessary and have always fought prescribing it as a result, any potentially interested manufacturer is likely to say there is not a big enough market to ofset setup costs or licencing costs ☹️☹️

You may also like...